GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » EPS (Diluted)

BioPlus Acquisition (BioPlus Acquisition) EPS (Diluted)

: $0.21 (TTM As of Jun. 2023)
View and export this data going back to 2022. Start your Free Trial

BioPlus Acquisition's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.21.

BioPlus Acquisition's EPS (Basic) for the three months ended in Jun. 2023 was $0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.21.

BioPlus Acquisition's EPS without NRI for the three months ended in Jun. 2023 was $0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $0.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


BioPlus Acquisition EPS (Diluted) Historical Data

The historical data trend for BioPlus Acquisition's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
EPS (Diluted)
- 0.07

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EPS (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 0.06 0.08 0.05

Competitive Comparison

For the Shell Companies subindustry, BioPlus Acquisition's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPlus Acquisition PE Ratio Distribution

For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's PE Ratio distribution charts can be found below:

* The bar in red indicates where BioPlus Acquisition's PE Ratio falls into.



BioPlus Acquisition EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

BioPlus Acquisition's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1.996-0)/29.310
=0.07

BioPlus Acquisition's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1.241-0)/24.482
=0.05

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioPlus Acquisition  (NAS:BIOS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


BioPlus Acquisition EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPlus Acquisition (BioPlus Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000